Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Lisata Therapeutics (LSTA) Stock Price & Analysis
1,018 Followers
LSTA Stock Chart & Stats
Day’s Range$2.83 - $2.99
52-Week Range― - ―
Previous Close$2.9
Volume3.33K
Average Volume (3M)N/A
Market Cap
$23.51M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 07, 2024EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$15.00Price Target Upside430.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Lisata Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LSTA FAQ
What was Lisata Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Lisata Therapeutics’s market cap?
Currently, no data Available
When is Lisata Therapeutics’s upcoming earnings report date?
Lisata Therapeutics’s upcoming earnings report date is May 07, 2024 which is in 17 days.
How were Lisata Therapeutics’s earnings last quarter?
Lisata Therapeutics released its earnings results on Feb 29, 2024. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.855 by $0.195.
Is Lisata Therapeutics overvalued?
According to Wall Street analysts Lisata Therapeutics’s price is currently Undervalued.
Does Lisata Therapeutics pay dividends?
Lisata Therapeutics does not currently pay dividends.
What is Lisata Therapeutics’s EPS estimate?
Lisata Therapeutics’s EPS estimate is -$0.73.
How many shares outstanding does Lisata Therapeutics have?
Currently, no data Available
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Lisata Therapeutics reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.855. Following the earnings report the stock price went up 5.802%.
Which hedge fund is a major shareholder of Lisata Therapeutics?
Among the largest hedge funds holding Lisata Therapeutics’s share is RA Capital Management. It holds Lisata Therapeutics’s shares valued at N/A.
---
Lisata Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (430.04% Upside)
$15.00 (430.04% Upside)
Hedge Fund Trend
Decreased
By 50.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.52%
12-Months-Change
Fundamentals
Return on Equity
-36.33%
Trailing 12-Months
Asset Growth
-25.11%
Trailing 12-Months
Company Description
Lisata Therapeutics
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
---
LSTA Company Deck
---
LSTA Earnings Call
Q4 2024
0:00 / 0:00
---
LSTA Stock 12 Months Forecast
Average Price Target
$15.00
▲(430.04% Upside)
Technical Analysis
Leap Therapeutics
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Karyopharm Therapeutics
―
Best Analysts Covering LSTA
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
+2.79%
reiterated a buy rating 2 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of +2.79% per trade.
---